{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:24:45Z","timestamp":1793982285582,"version":"4.8.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41409-026-03017-6","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:36:38Z","timestamp":1787135798000},"page":"1496-1503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treosulfan or busulfan plus clofarabine as reduced intensity conditioning regimen before allotransplant for adults with myeloid malignancies"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0549-959X","authenticated-orcid":false,"given":"Laura","family":"Prin-Felix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-6570","authenticated-orcid":false,"given":"Maxime","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0522-6976","authenticated-orcid":false,"given":"Amandine","family":"Le Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude-Marie","family":"Fourmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-8565","authenticated-orcid":false,"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-5581","authenticated-orcid":false,"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"3017_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ajh.27660","volume":"100","author":"N Gagelmann","year":"2025","unstructured":"Gagelmann N, Kr\u00f6ger N. Allogeneic stem cell transplant for myelofibrosis and myelodysplastic syndromes: a contemporary review. Am J Hematol. 2025;100:16\u201329.","journal-title":"Am J Hematol"},{"key":"3017_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"3017_CR3","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3017_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41409-023-02139-5","volume":"59","author":"A Spyridonidis","year":"2024","unstructured":"Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024;59:217\u201323.","journal-title":"Bone Marrow Transplant"},{"key":"3017_CR5","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3324\/haematol.2014.105981","volume":"99","author":"C Oudin","year":"2014","unstructured":"Oudin C, Chevallier P, Furst S, Guillaume T, El Cheikh J, Delaunay J, et al. Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. Haematologica. 2014;99:1762\u20138.","journal-title":"Haematologica"},{"key":"3017_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3324\/haematol.2014.119339","volume":"100","author":"MT Rubio","year":"2015","unstructured":"Rubio MT, Labopin M, Blaise D, Soci\u00e9 G, Contreras RR, Chevallier P, et al. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2015;100:683\u20139.","journal-title":"Haematologica"},{"key":"3017_CR7","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1002\/cam4.880","volume":"5","author":"P Chevallier","year":"2016","unstructured":"Chevallier P, Labopin M, de La Tour RP, Lioure B, Bulabois CE, Huynh A, et al. Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML\/MDS. Cancer Med. 2016;5:3068\u201376.","journal-title":"Cancer Med"},{"key":"3017_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/ajh.26620","volume":"97","author":"DW Beelen","year":"2022","unstructured":"Beelen DW, Stelljes M, Rem\u00e9nyi P, Wagner-Drouet EM, Dreger P, Bethge W, et al. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial. Am J Hematol. 2022;97:1023\u201334.","journal-title":"Am J Hematol"},{"key":"3017_CR9","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1182\/blood-2024-203964","volume":"144","author":"E Forcade","year":"2024","unstructured":"Forcade E, Devillier R, Hamel JF, M\u00e9ar JB, Bulabois CE, Bourhis JE, et al. Cyclosporine versus cyclosporine plus mycophenolate mofetil in reduced intensity allogeneic stem cell transplantation for intermediate-risk AML: a multi-center randomized study from the acute leukemia French intergroup, on behalf of the Filo, ALFA, and SFGM-TC Study Groups. Blood. 2024;144:4909.","journal-title":"Blood"},{"key":"3017_CR10","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1182\/blood-2024-198603","volume":"144","author":"R Peffault de Latour","year":"2024","unstructured":"Peffault de Latour R, Forcade E, Huynh A, Leclerc M, Nguyen Quoc S, Ceballos P, et al. Sequential intensified conditioning regimen allogeneic transplantation in younger adult patients with adverse-risk acute myeloid leukemia: a multi-center prospective study from the acute leukemia French intergroup on behalf of the Filo, ALFA, and SFGM-TC Study Groups. Blood. 2024;144:3483.","journal-title":"Blood"},{"key":"3017_CR11","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"M Aoudjhane","year":"2005","unstructured":"Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304\u201312.","journal-title":"Leukemia"},{"key":"3017_CR12","doi-asserted-by":"publisher","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","volume":"27","author":"BL Scott","year":"2021","unstructured":"Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, et al. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 Clinical Trial. Transplant Cell Ther. 2021;27:483.e1\u20136.","journal-title":"Transplant Cell Ther"},{"key":"3017_CR13","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1182\/blood-2022-164511","volume":"140","author":"R Devillier","year":"2022","unstructured":"Devillier R, Forcade E, Bay JO, Huynh A, Berceanu A, Peffault de Latour R, et al. Dose of IV busulfan in reduced toxicity conditioning regimen for older and\/or frail patients with AML or MDS. Blood. 2022;140:2381\u20132.","journal-title":"Blood"},{"key":"3017_CR14","doi-asserted-by":"publisher","first-page":"5447","DOI":"10.1007\/s12325-023-02696-7","volume":"40","author":"S Jeha","year":"2023","unstructured":"Jeha S, Goto H, Baruchel A, Bo\u00eblle-Le Corfec E, Geffriaud-Ricouard C, Pieters R, et al. Patient-level meta-analysis of clofarabine in acute lymphoblastic leukemia. Adv Ther. 2023;40:5447\u201363.","journal-title":"Adv Ther"},{"key":"3017_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.bcp.2009.06.094","volume":"78","author":"A Zhenchuk","year":"2009","unstructured":"Zhenchuk A, Lotfi K, Juliusson G, Albertioni F. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009;78:1351\u20139.","journal-title":"Biochem Pharmacol"},{"key":"3017_CR16","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1182\/blood.V96.10.3537","volume":"96","author":"D Genini","year":"2000","unstructured":"Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 2000;96:3537\u201343.","journal-title":"Blood"},{"key":"3017_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/10428199309064255","volume":"11","author":"V Gandhi","year":"1993","unstructured":"Gandhi V. Fludarabine for treatment of adult acute myelogenous leukemia. Leuk Lymphoma. 1993;11:7\u201313.","journal-title":"Leuk Lymphoma"},{"key":"3017_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ctrv.2013.03.006","volume":"39","author":"P Robak","year":"2013","unstructured":"Robak P, Robak T. Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev. 2013;39:851\u201361.","journal-title":"Cancer Treat Rev"},{"key":"3017_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3109\/10428194.2012.726722","volume":"54","author":"H Ghanem","year":"2013","unstructured":"Ghanem H, Kantarjian H, Ohanian M, Jabbour E. The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma. 2013;54:688\u201398.","journal-title":"Leuk Lymphoma"},{"key":"3017_CR20","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3324\/haematol.2014.108563","volume":"99","author":"P Chevallier","year":"2014","unstructured":"Chevallier P, Labopin M, Soci\u00e9 G, Tabrizi R, Furst S, Lioure B, et al. Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. Haematologica. 2014;99:1486\u201391.","journal-title":"Haematologica"},{"key":"3017_CR21","doi-asserted-by":"publisher","first-page":"36603","DOI":"10.18632\/oncotarget.26391","volume":"9","author":"A Le Bourgeois","year":"2018","unstructured":"Le Bourgeois A, Labopin M, Leclerc M, de Latour RP, Bourhis JH, Ceballos P, et al. Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire. Clofarabine\/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC. Oncotarget. 2018;9:36603\u201312.","journal-title":"Oncotarget"},{"key":"3017_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1182\/hematology.2025000738","volume":"2025","author":"N Ali","year":"2025","unstructured":"Ali N, Sandmaier BM. New age HCT conditioning regimens: what works and why? Hematol Am Soc Hematol Educ Program. 2025;2025:465\u201375.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3017_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/sj.bjc.6690043","volume":"79","author":"JA Hartley","year":"1999","unstructured":"Hartley JA, O\u2019Hare CC, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer. 1999;79:264\u20136.","journal-title":"Br J Cancer"},{"key":"3017_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.exphem.2005.09.015","volume":"34","author":"F Sj\u00f6\u00f6","year":"2006","unstructured":"Sj\u00f6\u00f6 F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M, et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol. 2006;34:115\u201321.","journal-title":"Exp Hematol"},{"key":"3017_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00280-007-0669-3","volume":"62","author":"D Munkelt","year":"2008","unstructured":"Munkelt D, Koehl U, Kloess S, Zimmermann SY, Kala\u00e4oui RE, Wehner S, et al. Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemother Pharmacol. 2008;62:821\u201330.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3017_CR26","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/bmt.2012.4","volume":"47","author":"A Shimoni","year":"2012","unstructured":"Shimoni A, Shem-Tov N, Volchek Y, Danylesko I, Yerushalmi R, Nagler A. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. Bone Marrow Transplant. 2012;47:1274\u201382.","journal-title":"Bone Marrow Transplant"},{"key":"3017_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/bmt.2011.88","volume":"47","author":"I Danylesko","year":"2012","unstructured":"Danylesko I, Shimoni A, Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike. Bone Marrow Transplant. 2012;47:5\u201314.","journal-title":"Bone Marrow Transplant"},{"key":"3017_CR28","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjh.17816","volume":"195","author":"P Patel","year":"2021","unstructured":"Patel P, Savani B, Byrne M. Treosulphan versus busulphan: pros and cons. Br J Haematol. 2021;195:304\u20135.","journal-title":"Br J Haematol"},{"key":"3017_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.591363","volume":"10","author":"S Zhu","year":"2020","unstructured":"Zhu S, Liu G, Liu J, Chen Q, Wang Z. Long-term outcomes of treosulfan- vs. busulfan-based conditioning regimen for patients with myelodysplastic syndrome and acute myeloid leukemia before hematopoietic cell transplantation: a systematic review and meta-analysis. Front Oncol. 2020;10:591363.","journal-title":"Front Oncol"},{"key":"3017_CR30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/MPH.0000000000002735","volume":"45","author":"W Wu","year":"2023","unstructured":"Wu W, Xue N, Yang H, Gao P, Guo J, Han D. Treosulfan versus busulfan-based conditioning in pediatric patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. J Pediatr Hematol Oncol. 2023;45:370\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"key":"3017_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.bbmt.2019.09.032","volume":"26","author":"J Peccatori","year":"2020","unstructured":"Peccatori J, Mastaglio S, Giglio F, Greco R, Crocchiolo R, Patriarca F, et al. Clofarabine and treosulfan as conditioning for matched related and unrelated hematopoietic stem cell transplantation: results from the Clo3o phase II trial. Biol Blood Marrow Transplant. 2020;26:316\u201322.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3017_CR32","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"3017_CR33","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"3017_CR34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"3017_CR35","doi-asserted-by":"crossref","unstructured":"Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Rem\u00e9nyi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7:e28\u201339.","DOI":"10.1016\/S2352-3026(19)30157-7"},{"key":"3017_CR36","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GVHD-free, relapse-free survival for registry-based studies: an ALWP\u2013EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610\u20131.","journal-title":"Bone Marrow Transplant"},{"key":"3017_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22:4\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3017_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389\u2013401.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3017_CR39","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3324\/haematol.2011.043810","volume":"96","author":"T Ruutu","year":"2011","unstructured":"Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, et al. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica. 2011;96:1344\u201350.","journal-title":"Haematologica"},{"key":"3017_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbmt.2010.05.007","volume":"17","author":"ER Nemecek","year":"2011","unstructured":"Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2011;17:341\u201350.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3017_CR41","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/bmt.2011.242","volume":"47","author":"J Casper","year":"2012","unstructured":"Casper J, Holowiecki J, Trenschel R, Wandt H, Schaefer-Eckart K, Ruutu T, et al. Allogeneic hematopoietic SCT in patients with AML following treosulfan\/fludarabine conditioning. Bone Marrow Transplant. 2012;47:1171\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"3017_CR42","doi-asserted-by":"publisher","first-page":"28.e1","DOI":"10.1016\/j.jtct.2024.11.001","volume":"31","author":"JS Schovsbo","year":"2025","unstructured":"Schovsbo JS, Kjeldsen L, N\u00f8rskov KH, Sengel\u00f8v H, Kornblit BT, Schj\u00f8dt I, et al. Outpatient management of patients conditioned with fludarabine and treosulfan prior to allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2025;31:28.e1\u201328.e10.","journal-title":"Transplant Cell Ther"},{"key":"3017_CR43","doi-asserted-by":"publisher","unstructured":"St\u00f6lzel F, Stelljes M, Beelen DW, Markiewicz M, Rem\u00e9nyi P, Luft T, et al. GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial. Haematologica. 2026:3. https:\/\/doi.org\/10.3324\/haematol.2025.288770. Epub ahead of print.","DOI":"10.3324\/haematol.2025.288770"},{"key":"3017_CR44","doi-asserted-by":"publisher","first-page":"294.e1","DOI":"10.1016\/j.jtct.2025.10.011","volume":"32","author":"J Pyka","year":"2026","unstructured":"Pyka J, Metzdorf J, Reicherts C, Marx J, Leimk\u00fchler N, Schneider A, et al. Treosulfan-based conditioning ameliorates the impact of pretransplantation measurable residual disease-positivity in acute myeloid leukemia patients allografted in remission. Transplant Cell Ther. 2026;32:294.e1\u201311.","journal-title":"Transplant Cell Ther"},{"key":"3017_CR45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjh.17817","volume":"195","author":"A Shimoni","year":"2021","unstructured":"Shimoni A, Robin M, Iacobelli S, Beelen D, Mufti GJ, Ciceri F, et al. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. Br J Haematol. 2021;195:417\u201328.","journal-title":"Br J Haematol"},{"key":"3017_CR46","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bcp.2010.09.027","volume":"81","author":"BC Valdez","year":"2011","unstructured":"Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol. 2011;81:222\u201332.","journal-title":"Biochem Pharmacol"},{"key":"3017_CR47","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.exphem.2015.02.001","volume":"43","author":"BC Valdez","year":"2015","unstructured":"Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, et al. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. Exp Hematol. 2015;43:448\u201361.e2.","journal-title":"Exp Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03017-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03017-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03017-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:36Z","timestamp":1793978856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03017-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3017"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03017-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Agreement was provided by the Ethic review Board of Nantes University Hospital (IRB 2025-DC-06).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All patients provided informed consent.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Ethics"}}]}}